These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14500492)

  • 21. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.
    Lehmann AK; Halstensen A; Aaberge IS; Holst J; Michaelsen TE; Sornes S; Wetzler LM; Guttormsen H
    Infect Immun; 1999 May; 67(5):2552-60. PubMed ID: 10225920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
    Preston MJ; Gerçeker AA; Reff ME; Pier GB
    Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design.
    Suker J; Feavers IM; Maiden MCJ
    Microbiology (Reading); 1996 Jan; 142 ( Pt 1)():63-69. PubMed ID: 8581171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.
    Tondella ML; Popovic T; Rosenstein NE; Lake DB; Carlone GM; Mayer LW; Perkins BA
    J Clin Microbiol; 2000 Sep; 38(9):3323-8. PubMed ID: 10970378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
    Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.
    Wedege E; Caugant DA; Musacchio A; Saunders NB; Zollinger WD
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):639-42. PubMed ID: 10391880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.
    Luijkx TA; van Dijken H; Hamstra HJ; Kuipers B; van der Ley P; van Alphen L; van den Dobbelsteen G
    Infect Immun; 2003 Nov; 71(11):6367-71. PubMed ID: 14573657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design.
    Oomen CJ; Hoogerhout P; Kuipers B; Vidarsson G; van Alphen L; Gros P
    J Mol Biol; 2005 Sep; 351(5):1070-80. PubMed ID: 16038932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis.
    Jansen C; Kuipers B; van der Biezen J; de Cock H; van der Ley P; Tommassen J
    FEMS Immunol Med Microbiol; 2000 Mar; 27(3):227-33. PubMed ID: 10683467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.
    Toropainen M; Saarinen L; Vidarsson G; Käyhty H
    Infect Immun; 2006 May; 74(5):2803-8. PubMed ID: 16622217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of meningococcal epitopes in LamB of Escherichia coli and the stimulation of serosubtype-specific antibody responses.
    McCarvil J; McKenna AJ; Grief C; Hoy CS; Sesardic D; Maiden MC; Feavers IM
    Mol Microbiol; 1993 Oct; 10(1):203-13. PubMed ID: 7526119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis.
    Humphries HE; Williams JN; Blackstone R; Jolley KA; Yuen HM; Christodoulides M; Heckels JE
    Vaccine; 2006 Jan; 24(1):36-44. PubMed ID: 16105711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards.
    Naess LM; Rosenqvist E; Høiby EA; Michaelsen TE
    J Immunol Methods; 1996 Sep; 196(1):41-9. PubMed ID: 8841442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunisation with phage-displayed variable region 2 from meningococcal PorA outer membrane protein induces bactericidal antibodies against Neisseria meningitidis.
    Menéndez T; De Haz I; Delgado M; Garay H; Martín A; Vispo NS
    Immunol Lett; 2001 Oct; 78(3):143-8. PubMed ID: 11578688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.
    Zhu D; Williams JN; Rice J; Stevenson FK; Heckels JE; Christodoulides M
    Infect Immun; 2008 Jan; 76(1):334-8. PubMed ID: 17967859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production and functional characterization of two mouse/human chimeric antibodies with specificity for the tumor-associated Tn-antigen.
    Oppezzo P; Osinaga E; Tello D; Bay S; Cantacuzene D; Irigoín F; Ferreira A; Roseto A; Cayota A; Alzari P; Pritsch O
    Hybridoma; 2000 Jun; 19(3):229-39. PubMed ID: 10952411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.
    Luijkx TA; van Gaans-van den Brink JA; van Dijken HH; van den Dobbelsteen GP; van Els CA
    Clin Vaccine Immunol; 2008 Oct; 15(10):1598-605. PubMed ID: 18768670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis.
    Tauseef I; Ali YM; Bayliss CD
    Infect Immun; 2013 Apr; 81(4):1374-80. PubMed ID: 23403557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice.
    Peeters CC; Claassen IJ; Schuller M; Kersten GF; van der Voort EM; Poolman JT
    Vaccine; 1999 Jun; 17(20-21):2702-12. PubMed ID: 10418921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.